Bristol Myers Squibb Strengthens Position in Obstructive Hypertrophic Cardiomyopathy with New Camzyos (mavacamten) Data Presented at ACC 2026 Bristol Myers Squibb has unveiled an extensive body of new clinical and real-world evidence supporting the continued evolution of Camzyos (mavacamten) as…
KalVista Pharmaceuticals to Showcase New Clinical Data on EKTERLY® (Sebetralstat) at the 2026 Global Angioedema Leadership Conference KalVista Pharmaceuticals has announced a significant scientific presence at the upcoming 2026 Global Angioedema Leadership Conference, highlighting its continued commitment to advancing treatment…
Bristol Myers Squibb Redefines First-Line Treatment Landscape in Classical Hodgkin Lymphoma with Expanded U.S. and EU Approvals for Opdivo® (nivolumab) Bristol Myers Squibb today announced that Opdivo® (nivolumab) has received approval for two new classical Hodgkin Lymphoma (cHL) indications in the U.S.…
Board Reconstitution at Genmab A/S Accompanied by Employee Grants of Restricted Stock Units and Warrants Genmab A/S has announced key governance updates and employee incentive decisions following the conclusion of its Annual General Meeting (AGM) held on March 19, 2026.…
TALZENNA in Combination with XTANDI Shows Marked Improvement in Radiographic Progression-Free Survival for Patients with Metastatic Prostate Cancer Pfizer Inc. has announced compelling topline results from its Phase 3 TALAPRO-3 clinical trial, marking a potentially significant advancement in the treatment…
Celltrion Launches AVTOZMA® (tocilizumab-anoh) Subcutaneous Formulation in the U.S. Market Celltrion has announced a significant milestone in its ongoing efforts to expand access to biologic therapies in the United States, confirming that its biosimilar product AVTOZMA® (tocilizumab-anoh) is now commercially…
Pfizer reports positive Phase 2 topline results for next-generation CDK4 inhibitor atirmociclib in second-line metastatic breast cancer Pfizer Inc. today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or…
ICON plc announces revised timeline for Q4 and full-year 2025 earnings as investigation into accounting practices continues. ICON plc, today announced that it intends to release its fourth quarter and full year 2025 earnings results on or prior to April 30,…
FDA Expands Approval of GSK’s RSV Vaccine Arexvy to Include At-Risk Adults Aged 18–49 GSK plc today announced that the US Food and Drug Administration (FDA) has expanded the approved age indication of Arexvy (Respiratory Syncytial Virus vaccine, [adjuvanted]) to…
Johnson & Johnson Reports Encouraging First-in-Human Data for Erda-iDRS (formerly TAR-210) in Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Johnson & Johnson today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients…
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan Curatis Holding AG and Neupharma Co., Ltd. a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology…
Planet DDS 2026 Dental Outlook Shows More New Patients, Fewer No-Shows Across the Industry Planet DDS, a leading provider of cloud-based, enterprise-grade dental software solutions, announced the release of its 2026 Dental Industry Outlook, an annual benchmark report designed to help…